While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

so the big question is whether Keytruda can do better in BTC than Imfinzi, which improved OS by 20% when added to chemo in the TOPAZ-1 trial reported in 2021. That earned Imfinzi an FDA approval ...

Keytruda is already approved for the indication, based on interim results reported in 2021 that showed a 32% ... The AI effect in pharma commercial strategy: From data to re ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S. drugmaker's ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

According to McKinsey, the medical industry’s overall profits are projected to grow at a compound annual growth rate (CAGR) of 4%, increasing from $654 billion in 2021 to $790 billion by 2026.

SoFi began trading in June 2021, closing its first day at $22.65 ... Investors hope the company’s transition from clinical to commercial stage will be lucrative. ImmunityBio has navigated ...